Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

The daily pill, called ritlecitinib or litfulo, could help up to 14,000 people ... including a reduced price from the manufacturer Pfizer. Without a discount, a packet of 30 capsules would ...

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products ...

Called Ritlecitinib or Litfulo, it could help thousands of people ... including a reduced price from the manufacturer Pfizer. Helen Knight, director of medicines evaluation at NICE, said: "Our ...